Trevi Therapeutics, Inc. TRVI Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.19M-27.6% | -$8.32M+27.1% | -$11.8M+10.9% | -$12.3M+0.4% | -$10.34M+5.2% | ||
| $34K-8.1% | $31K-18.4% | $38K+5.6% | $38K0.0% | $37K+5.7% | ||
| $2.19M+81.4% | $1.35M+47.2% | $1.24M+51.2% | $1.38M+22.8% | $1.21M+67.1% | ||
| -$1.48M+25.6% | —— | -$282K-317% | —— | -$1.99M-778% | ||
| -$1.08M+28.4% | -$555K— | —— | —— | -$1.5M-59.7% | ||
| $2.84M+369% | —— | $30K+104% | $1M+175% | $605K+204% | ||
| $105K-6.3% | $107K-46.0% | $108K+272% | $110K-2.7% | $112K-6.7% | ||
| -$16.69M-23.8% | -$7.63M+20.1% | -$10.88M-13.9% | -$10.1M-16.3% | -$13.48M-28.8% | ||
| $102K— | —— | $12K— | —— | —— | ||
| $25.55M+45.2% | $23.79M+11.5% | $20.68M-0.2% | $14.5M+13.7% | $17.6M-20.6% | ||
| $16.97M+270% | -$30.61M-28.2% | -$50.94M-764% | -$2.61M— | -$9.95M-23.0% | ||
| $222K-69.1% | $225K+1,631% | $1.12M+589% | $13K-93.9% | $718K+17,850% | ||
| —— | $0-100% | $0-100% | $0-100% | $11K-65.6% | ||
| $222K-97.4% | $284K-99.4% | $1.63M-67.3% | $110.4M+2,079% | $8.71M+31,189% | ||
| $498K+103% | -$37.96M-310% | -$60.19M-2,048% | $97.68M+11,619% | -$14.72M+20.8% | ||
| $431K+9.1% | $562K+89.2% | $298K-15.6% | $383K+14.0% | $395K+3.7% | ||
| $2.84M+369% | —— | $30K+104% | $1M+175% | $605K+204% | ||
| $105K-6.3% | $107K-46.0% | $108K+272% | $110K-2.7% | $112K-6.7% | ||
| —— | $6.5K— | $6.5K— | $6.5K— | $6.5K— | ||
| $25.55M+45.2% | $23.79M+11.5% | $20.68M-0.2% | $14.5M+13.7% | $17.6M-20.6% | ||
| —— | $0-100% | $0-100% | $0-100% | $11K-65.6% | ||
| —— | $0— | $219K— | $368K— | $222K— | ||
| —— | $27.04M+130% | $27.04M+130% | $27.04M+130% | $27.04M+130% | ||
| —— | —— | —— | $2.54M— | $8.22M— | ||
| —— | —— | —— | —— | —— | ||
| -$16.79M— | -$7.63M+20.2% | -$10.89M-14.0% | —— | —— | ||
| -$16.79M— | -$7.63M+20.2% | -$10.89M-14.0% | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Trevi Therapeutics, Inc. generate?
- Trevi Therapeutics, Inc. (TRVI) generated -$45.3M in operating cash flow over the trailing twelve months.
- What is Trevi Therapeutics, Inc.'s free cash flow?
- After $143.0K of capital expenditures, Trevi Therapeutics, Inc.'s free cash flow was -$44.9M over the trailing twelve months, down 35.4% year over year.
- Where does Trevi Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.